Sanofi is increasing its R&D presence in China, announcing plans to open a global research hub focused on data analysis in Chengdu. The French firm said this confirms China as the “third pillar ...

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to ...

French drugmaker Sanofi’s confirmation yesterday that it plans to sell a controlling stake in its over-the-counter unit to a ...

Houman Ashrafian, MD, PhD Executive Vice President, Head of Research and Development at Sanofi "China has the largest number of people living with COPD worldwide, and a significant proportion of ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has approved Dupixent as an add-on maintenance treatment for adults with ...

Plus, news about TenNor Therapeutics, Gan & Lee Pharmaceuticals, Orasis and Optus Pharmaceuticals: Exscientia receives $15M milestone from Sanofi: The companies are advancing two programs as ...

France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the ...

Houman Ashrafian, MD, PhD, executive vice president, head of research and development at Sanofi, said: “China has the largest number of people living with COPD worldwide, and a significant proportion ...